Caelum Biosciences, a Fortress Biotech Company, is a clinical stage biotechnology company developing treatments for rare and life-threatening conditions. Caelum’s lead asset, CAEL-101, is a novel antibody in Phase 1b clinical trials that is being developed for patients with AL Amyloidosis. Caelum holds two Orphan Drug Designations for CAEL-101, one for use as a therapeutic agent for patients with AL amyloidosis and one for use as a radioimaging agent in amyloidosis. Interim Phase 1a/1b data on CAEL-101 was presented at the American Society of Hematology meeting in December 2016.
For more information, please visit www.caelumbio.com.